Portola Pharmaceuticals, which is developing therapeutics for patients suffering from blood clots, filed on Friday with the SEC to raise up to $115 million in an initial public offering. The South San Francisco, CA-based company, which booked $72 million in sales for the 12 months ended 12/31/2012, plans to list on the NASDAQ under the symbol PTLA. Portola Pharmaceuticals initially filed confidentially on 12/21/2012. Morgan Stanley and Credit Suisse are the joint bookrunners on the deal. No pricing terms were disclosed.
